Reimbursed Care Access in Réunion

Currently classified as a strictly controlled substance under French national drug scheduling laws, with no authorized medical use outside of approved clinical research. The French government confirms psilocybin is listed on the arrêté of 22 February 1990 fixing the list of substances classified as stupéfiants; production, possession, importation and use are prohibited except under express ANSM authorisation for research. #

Currently classified as a strictly controlled substance under national drug scheduling laws and illegal for routine clinical or recreational use; access for therapeutic use in Réunion/France is limited to authorised clinical trials or tightly controlled research programmes. Law enforcement and public‑health bodies continue to treat MDMA as an illicit stimulant, while national monitoring bodies document MDMA only in surveillance and research contexts (no routine reimbursed treatment pathway). #

Esketamine (SPRAVATO) holds a regulated medical role in France and is the only listed psychedelic‑class medication with a formal reimbursement decision from the French health authorities under defined conditions. The Haute Autorité de Santé (HAS) has issued an opinion supporting maintenance of reimbursement for SPRAVATO when used in combination with an oral SSRI or SNRI for adults under 65 with severe treatment‑resistant depressive episodes who have not responded to at least two different oral antidepressants in the current episode; HAS details the specific population, the required association with an oral antidepressant and age restriction in its published opinion. Reimbursement and prescription are governed by the national regulatory framework and hospital/psychiatric care pathways; implementation in Réunion follows the national rules (dispensing and administration in authorised hospital settings, specific monitoring and reporting requirements). #

Ketamine is an established anesthetic and analgesic widely used and reimbursed within standard hospital practice in France; for psychiatric indications (notably treatment‑resistant depression) intravenous or subcutaneous ketamine is used off‑label in specialised hospital settings and is not a nationally reimbursed, routine outpatient antidepressant with an approved marketing authorisation for depression. French expert discussions and specialty guidance note ketamine infusions are administered under strict clinical supervision in hospital settings and are considered off‑label for depression (frequently considered a second‑line add‑on when esketamine is not appropriate), with centre‑by‑centre variability in access and funding—some hospital administrations absorb costs while outpatient/private infusions may not be covered by public insurance. French clinical and addictovigilance panels have explicitly described ketamine’s off‑label psychiatric use and the need for monitored hospital pathways. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT and most plant sources containing it are listed under French stupéfiants regulations and require an express ANSM authorisation for any lawful medical or research use. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT falls within the broader class of scheduled tryptamine derivatives regulated under French narcotics law; routine therapeutic or sacramental use is not permitted outside ANSM‑authorised trials. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. France classifies ibogaine/iboga among controlled substances; administrative and judicial rulings have reinforced its controlled status. Any use would require explicit ANSM authorisation in the research context. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Although historical court cases (e.g., Santo Daime) briefly affected legal interpretation, French authorities subsequently listed ayahuasca ingredients and harmala alkaloids as stupéfiants; possession, administration and importation are prohibited except under express ANSM authorisation for research. Religious exemptions are not available under French law in the same way as in some other jurisdictions. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline (and peyote-derived mescaline) is listed among controlled hallucinogenic substances under French narcotics legislation, barring routine medical prescribing or possession except with ANSM‑authorised research approval. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Members of the 2C family (for example 2C‑B) are explicitly treated as stupéfiants in France; surveillance reports and OFDT documentation classify 2C compounds as controlled new psychoactive substances with no routine medical pathway. #